The negative trading movement is likely a direct response to the market's interpretation of the FDA meeting outcomes. While the specifics of the outcomes are not detailed, the market reaction suggests that investors may have been expecting more positive news or a clearer path to advancement for NGC-Cap. This could potentially delay the drug's development or raise concerns about its efficacy or market potential, thus negatively impacting investor sentiment in the short term.